Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics Softcover reprint of the original 1st ed. 2006 Edition

From the reviews:

“Colin J. Barnstable and co-workers have undertaken the task to present an up-to-date collection including presentations on clinical and mechanistic data as well as current therapeutic applications. The 412-page hardback book includes numerous black-and-white pictures as well as several illustrations. … The book … will surely find a place not only for the use of basic scientists but could be of interest for the clinician trying to understand the background on angiogenesis research.” (Antonia Joussen, Graefes Archive for Clinical and Experimental Ophthalmology, Issue 246, 2008)

The recent intense study of pathogenic ocular angiogenesis-an abnormal growth of blood vessels in the eye responsible for the major blinding diseases throughout the world-has yielded an overwhelming flood of scientific findings, novel insights, and possible future therapeutic approaches. In Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics, leading academic and pharmaceutical researchers and clinicians from many disciplines synthesize and summarize these developments to present a comprehensive review of what is known about angiogenesis, its role in blinding diseases, and the mechanisms leading to progressive vessel dysfunction. The authors also identify and assess the most promising approaches with potential for commercial exploitation and discuss the challenges encountered in developing therapeutics for ocular neovascular diseases. Highlights include illuminating chapters on gene therapy and novel drug delivery systems and excellent summaries of the newest therapeutic approaches.
Comprehensive and multidisciplinary, Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics offers a novel view of the clinical features of pathological angiogenesis in the eye, the molecular and environmental switches that govern vessel growth, and the tremendous opportunities for and progress made in the development of new therapeutics.